施保利通与利可君治疗小儿感染继发粒细胞缺少症的疗效

Effects of of Esberitox and Leucogen for Treatment of Pediatric Infection Lead to Neutropenia

关键词:  施保利通  利可君  粒细胞缺少  药物联用  小儿感染

Key words:  Esberitox  Leucogen  neutropenia  drug combination  pediatric infection

摘要:

目的 探讨施保利通与利可君治疗小儿感染继发粒细胞缺少症的疗效。方法 回顾性分析2013年1月— 2017年3月80例感染继发粒细胞缺少症的患儿，根据服用升白细胞药物种类不同分为对照组（n=20）、施保利通组（n=20）、利可君组（n=20）和联用组（n=20），均给予抗感染和对症治疗。治疗前后3~7 d，比较4组患儿白细胞、粒细胞升高的比例、感染控制率和住院天数等。结果 与对照组相比，利可君组和联用组患者白细胞、粒细胞比值显著升高（P<0.05），住院天数显著缩短（P<0.05）；与施保利通组比较，联用组白细胞、粒细胞比值显著升高（P<0.05）。各组退热天数、CRP正常天数、咳嗽气喘天数无显著差异。结论 利可君组、施保利通与利可君联用组可明显促进患者的白细胞、粒细胞恢复，有助于缩短患者住院天数，未见明显不良反应。

Abstract:

OBJECTIVE To evaluate the clinical efficacy of Esberitox and Leucogen treating pediatric infection which lead to neutropenia. METHODS A total of 80 children with neutropenia in pediatric inpatient department from January 2013 to March 2017 were analyzed retrospectively. According to the different kinds of medicine, patients were divided into four groups:control group, Esberitox group, Leucogen group and combination group, 20 cases in each group were given symptomatic treatment. Comparing of the proportion of increasing eukocyte and granulocyte of controlling infection, the rate of controlling infection, the days of hospitalization in the four guoups during giving treantment after 3-7 d. RESULTS The ratio of leukocyte to granulocyte in Leucogen group and combination group was significantly higher than that in the control group (P<0.05), and the days of hospitalization in Leucogen group and combination group were shorter than the control group (P<0.05). The rate of leukocyte and granulocyte in combination group was higher than the Esberitox group (P<0.05). The days of abatement of fever, the normal days of CRP, the days of cough had no difference in the four groups. CONCLUSION Leucogen group and combination group can improve leukocyte and granulocyte count back to normal, they shorter hospitalization days. There is no obvious adverse reaction between the two groups.